Presentation ACC 2017 Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk Presenter: Marc Sabatine March 17, 2017
Presentation SIF 2017 A Case That Went “South-ard”: 63 yo Male p/w progressive Presenter: Jeffrey A. Southard March 10, 2017
News Daily News A Deadly Diet: Half of US Deaths From Cardiometabolic Causes Linked to Dietary Habits Michael O'Riordan March 08, 2017
News Daily News Apples and Pears: Genetic Analysis Points to Causal Role for Belly Fat in Heart Disease and Diabetes Yael L. Maxwell February 14, 2017
Presentation JIM 2017 Dedicated Designed DES+ for Diabetic Patients Presenter: Dinesh Shah February 10, 2017
News Daily News Major CVD Outcomes Trial Testing PCSK9 Inhibitor Evolocumab Meets Primary Endpoint Michael O'Riordan February 03, 2017
News Daily News Women Without Diabetes Fare as Poorly as Diabetic Men Post-PCI L.A. McKeown January 30, 2017
News Features Year in Review: Physicians Pick the Biggest News of 2016, in Interventional Cardiology and Beyond Shelley Wood December 30, 2016
News Features Repaso del Año: Los Médicos Eligen las Noticias Más Importantes de 2016 en Cardiología Intervencionista y Más Shelley Wood December 30, 2016
News Daily News FDA Approves CV Death Reduction Claim for Empagliflozin in Type 2 Diabetes Shelley Wood December 02, 2016
News Daily News PCSK9 Variants Linked With Lower LDL Cholesterol, Increased Diabetes Risk Michael O'Riordan December 01, 2016
News Daily News Las Variantes del Gen PCSK9 se asocian a Niveles Más Bajos de Colesterol LBD y a un Mayor Riesgo de Diabetes Michael O'Riordan December 01, 2016
News Features Run, Walk, Bike: Doctors Open Up About Their Own Heart-Healthy Exercise Habits Michael O'Riordan November 11, 2016
News Daily News Más Quelación: Se Aprueba el Ensayo TACT2 para el Controvertido Tratamiento Post-IM en Pacientes Diabéticos Shelley Wood September 28, 2016
News Daily News Chelation Encore: TACT2 Trial Gets Go-ahead for Controversial Post-MI Treatment in Diabetes Shelley Wood September 28, 2016
News Daily News Semaglutide Cuts Risk of Major Cardiovascular Events in Type 2 Diabetes: SUSTAIN-6 Michael O'Riordan September 16, 2016